Properties (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:activeDuring |
cemiplimab
|
| gptkbp:administrativeDivision |
every 2 weeks
|
| gptkbp:approves |
non-small cell lung cancer
head and neck squamous cell carcinoma cutaneous squamous cell carcinoma |
| gptkbp:chemicalFormula |
IgG4 monoclonal antibody
|
| gptkbp:clinicalTrials |
combination therapy
Phase 3 monotherapy NCT03422023 NCT03422036 NCT03433100 NCT03433113 |
| gptkbp:developedBy |
gptkb:Regeneron_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
Libtayo
|
| gptkbp:lastProduced |
gptkb:European_Union
gptkb:United_States |
| gptkbp:mandates |
advanced skin cancer
advanced head and neck cancer advanced lung cancer |
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:Japan gptkb:Switzerland brand_name_Libtayo |
| gptkbp:patentAssignee |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:patentType |
September 2021
|
| gptkbp:researchFocus |
quality of life
cancer treatment immunotherapy tumor microenvironment clinical outcomes long-term effects treatment resistance patient selection PD-1 pathway combination strategies biomarker_identification |
| gptkbp:route |
intravenous infusion
|
| gptkbp:safetyFeatures |
infusion-related reactions
immune-mediated adverse reactions potential for fetal harm |
| gptkbp:sideEffect |
fatigue
nausea diarrhea rash pruritus |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
cancer
|
| gptkbp:triggerType |
PD-1 inhibition
|